Ingredient Testing Doesn't Predict a Finished Joint Supplement's Results

• Glucosamine and chondroitin have been studied for decades, producing small and inconsistent pain-relief results across systematic reviews.
• Cartigenix HP® with RestorCel® has been evaluated as a complete formulation across three published human studies.*

Scottsdale, AZ, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Many joint and cartilage supplements are built around a single well-studied ingredient, while the finished product may never have been tested as a whole. Glucosamine and chondroitin are the two most common ingredients in the joint health category, and although they are well-studied, the results on their efficacy are mixed and inconsistent. Calroy Health Sciences, the science-driven dietary supplement company behind Cartigenix HP® with RestorCel®, instead uses next generation ingredients, and researched the complete, finished formulation in human studies rather than relying on ingredient-level data alone.

"I recommended glucosamine and chondroitin to patients for years," says Tom Bayne, DC, educator with Calroy Health Sciences, who has worked in chiropractic and functional medicine for nearly three decades. "It was the standard of care, and there wasn't much else to point to. The honest answer when patients asked if it would work was 'maybe.' What's different now is that we have published research, including a placebo-controlled study, with measurable outcomes on a new supplement. That gives clinicians and patients confidence."

Myth: If an Ingredient Is Well-Studied, the Finished Product Built Around It Works the Same Way

Glucosamine and chondroitin are both structural components of cartilage tissue, so supplementing them to support the cartilage they build is logical. But although glucosamine and chondroitin have been studied for decades, systematic reviews and meta-analyses have generally reported small or inconsistent pain-score differences compared with placebo. Plus, a well-studied ingredient does not automatically transfer its research record to every finished product that happens to contain it, nor does it indicate that the compound is effective. Dosage, ingredient interactions, and standardization are key components to a successful supplement formula.

Myth: A Supplement Company Only Needs to Show Its Ingredients Work, Not Its Finished Product

Joint supplement research may stop at the ingredient level because testing a finished, multi-compound formulation in a human trial costs more and takes longer than citing existing ingredient literature. Cartigenix HP with RestorCel, a proprietary blend of 13 bioactive compounds including serratol from Boswellia serrata and a standardized North India celery seed extract, has instead been evaluated as a complete product across three published human studies, including a placebo-controlled trial: Desai 2022 (prospective, n=1,236), Desai 2024 (observational, n=394), and Vaidya 2025 (randomized controlled, n=62). The studies used the full proprietary Restorcel blend, so the findings apply to Cartigenix HP directly.

Myth: Placebo-Controlled Studies are Common for Dietary Supplements

Very few dietary supplement companies invest in placebo-controlled research trials, especially on the full formulation. This type of research is not required for dietary supplements, and is very costly and time-consuming. For these reasons, randomized, placebo-controlled trials are often treated as exclusive to drug development, where dietary supplement companies may rely on existing research on specific ingredients. Cartigenix HP stands out in the space, with placebo-controlled research on the full formulation. The Vaidya 2025 study, the placebo-controlled trial in the Cartigenix HP research profile, documented a 64% average reduction in WOMAC Pain Scale scores, a validated clinical outcome measure, alongside a 50% average improvement in walking distance on the six-minute walk test over 90 days.*† The trial also recorded measurable cartilage regeneration biomarkers at the same 90-day point, with some participants reporting noticeable changes as early as 15 days.*† 

As the supplement industry faces pressure to show finished-product evidence rather than ingredient-level rationale, the distinction between the two is likely to keep shaping which products researchers, clinicians, and consumers are able to evaluate on data instead of assumption.

Frequently Asked Questions

Question: What makes a joint supplement science-backed rather than marketing?
Answer: Look for human studies conducted on the finished product, not just its individual ingredients, published in peer-reviewed journals. The strongest designs are randomized, placebo-controlled trials using validated measures such as the WOMAC Pain Scale and the six-minute walk test. Ingredient-level claims alone do not necessarily establish that a complete formulation works.

Question: What does "cartilage-focused" mean in a joint supplement?
Answer: A cartilage-focused supplement is formulated to target cartilage at the structural level, rather than simply addressing joint comfort alone. Cartigenix HP with RestorCel is one example, evaluated in three published human studies, including a placebo-controlled trial that measured cartilage regeneration biomarkers alongside pain and mobility outcomes.*†

Question: Can a joint supplement be taken long-term without a prescription?
Answer: In general, dietary supplements are not regulated by the FDA, and do not require a doctor’s prescription. Individuals with medical conditions or taking prescription medications should consult a healthcare provider before starting any supplement.

Question: Is a cartilage-focused joint formula suitable for vegan or allergy-conscious users?
Answer: Some are, though formulations vary, so it is important to read labels. The finished formulation of Cartigenix HP with RestorCel is vegan, non-GMO, and free from gluten, dairy, and soy. This distinguishes it from glucosamine and chondroitin, which are often derived from shellfish or animal cartilage. Anyone with allergies should confirm sourcing before use.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

†As shown in a placebo-controlled, randomized, controlled human research study (Vaidya 2025) and an observational study (Desai 2024). A prospective study (n=1,236) similarly demonstrated significant improvements in pain scores, along with quality of life measures (Desai 2022).

About Calroy Health Sciences
Calroy Health Sciences is a science-driven dietary supplement company dedicated to supporting foundational health. Co-founded by CEO Ed Hoyt and Chief Scientific Officer Chen Chen, PhD, Calroy brings more than three decades of combined experience in the dietary supplement industry. The company's breakthrough products — Arterosil HP® with MonitumRS®, Vascanox HP® with Noxa24®, and Cartigenix HP® with RestorCel® — are developed through a research-first approach that includes studying the finished formulated product, not just individual ingredients.

Calroy's research has been published in peer-reviewed journals and is conducted in partnership with major academic institutions, leading clinicians and researchers. The company also holds patents on its products and its microfluidic chip testing technology. For more information, visit calroy.com.

Sarah Evans 
Head of PR, Zen Media 
sarah@zenmedia.com